Skip to main content

Advertisement

SpringerLink
Log in

Annexin A10 is a marker for the serrated pathway of colorectal carcinoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Serrated adenocarcinoma (SAC), representing at least 10 % of colorectal carcinomas (CRC), differs from conventional carcinomas not only by its histology, but also by its molecular basis. However, the diagnosis of SAC in poorly differentiated cases and without an adjacent serrated adenoma can be challenging. In this study, we utilized previously described expression data and identified annexin A10 (ANXA10) as a potential marker for SAC. We conducted ANXA10 immunohistochemistry in groups of 146 CRC patients and 131 serrated and conventional polyps. In CRC cases, ANXA10 expression associated with serrated histology (sensitivity 42 % and specificity 98 %). BRAF V600E mutation correlated with ANXA10 expression but also seven BRAF wild-type tumors (5 %) were positive for ANXA10. Immunoreactivity for either ANXA10 or BRAF V600E was an accurate predictor of serrated histology (sensitivity 55 % and specificity 97 %). ANXA10 expression did not associate with tumor stage or grade. Of the 131 colorectal polyps, 30/30 of sessile serrated adenomas, 6/11 traditional serrated adenomas, 20/32 hyperplastic polyps, and 2/27 tubulovillous adenomas were positive for ANXA10, while 31/31 tubular adenomas were negative. In conclusion, the results suggest that ANXA10 is a marker with high specificity for the serrated pathway of CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ANXA10:

Annexin A10

CC:

Conventional adenocarcinoma

CRC:

Colorectal cancer

GCHP:

Goblet cell rich hyperplastic polyp

HP:

Hyperplastic polyp

IHC:

Immunohistochemistry

MAPK-ERK:

Mitogen-activated protein kinase-extracellular signal-regulated kinase

MMR:

Mismatch repair

MSI:

Microsatellite instability

MVHP:

Microvesicular hyperplastic polyp

SAC:

Serrated adenocarcinoma

SSA:

Sessile serrated adenoma

TMA:

Tissue microarray

TSA:

Traditional serrated adenoma

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer Statistics, 2014. CA Cancer J Clin 64:9–29. doi:10.3322/caac.21208

    Article  PubMed  Google Scholar 

  2. O’Brien MJ, Yang S, Huang CS et al (2008) The serrated polyp pathway to colorectal carcinoma. Diagn Histopathol 14:78–93. doi:10.1016/j.mpdhp.2007.12.003

    Article  Google Scholar 

  3. Mäkinen MJ, George SM, Jernvall P et al (2001) Colorectal carcinoma associated with serrated adenoma—Prevalence, histological features, and prognosis. J Pathol 193:286–294. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2

    Article  PubMed  Google Scholar 

  4. Makinen MJ (2007) Colorectal serrated adenocarcinoma. Histopathology 50:131–150. doi:10.1111/j.1365-2559.2006.02548.x

    Article  CAS  PubMed  Google Scholar 

  5. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113–130. doi:10.1111/j.1365-2559.2006.02549.x

    Article  CAS  PubMed  Google Scholar 

  6. Tuppurainen K, Makinen JM, Junttila O et al (2005) Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol 207:285–294. doi:10.1002/path.1850

    Article  CAS  PubMed  Google Scholar 

  7. Snover D, Ahnen D, Burt R, Odze R (2010) Serrated polyps of the colon and rectum and serrated (“hyperplastic”) polyposis. WHO Classif. tumours. Pathol. Genet. Tumours Dig. Syst. Berlin Springer-Verlag (4th Ed)

  8. García-Solano J, Pérez-Guillermo M, Conesa-Zamora P et al (2010) Clinicopathologic study of 85 colorectal serrated adenocarcinomas: Further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol 41:1359–1368. doi:10.1016/j.humpath.2010.04.002

    Article  PubMed  Google Scholar 

  9. Kambara T, Simms LA, Whitehall VLJ et al (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53:1137–1144. doi:10.1136/gut.2003.037671

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. O’Brien MJ, Yang S, Mack C et al (2006) Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 30:1491–1501. doi:10.1097/01.pas.0000213313.36306.85

    Article  PubMed  Google Scholar 

  11. McGivern A, Wynter CV, Whitehall VL et al (2004) Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 3:101–107

    Article  CAS  PubMed  Google Scholar 

  12. Poynter JN, Siegmund KD, Weisenberger DJ et al (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17:3208–3215. doi:10.1158/1055-9965.EPI-08-0512

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Spring KJ, Zhao ZZ, Karamatic R et al (2006) High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 131:1400–1407. doi:10.1053/j.gastro.2006.08.038

    Article  CAS  PubMed  Google Scholar 

  14. Burnett-Hartman AN, Newcomb PA, Potter JD et al (2013) Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 73:2863–2872

    Article  CAS  PubMed  Google Scholar 

  15. Stefanius K, Ylitalo L, Tuomisto A et al (2011) Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 58:679–692. doi:10.1111/j.1365-2559.2011.03821.x

    Article  PubMed Central  PubMed  Google Scholar 

  16. Sajanti SA, Sirniö P, Väyrynen JP et al (2014) VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Arch. doi:10.1007/s00428-014-1555-0

    Google Scholar 

  17. Laiho P, Kokko A, Vanharanta S et al (2007) Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26:312–320. doi:10.1038/sj.onc.1209778

    Article  CAS  PubMed  Google Scholar 

  18. Conesa-Zamora P, García-Solano J, García-García F et al (2013) Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. Int J Cancer 132:297–307. doi:10.1002/ijc.27674

    Article  CAS  PubMed  Google Scholar 

  19. Mussunoor S, Murray G (2008) The role of annexins in tumour development and progression. J Pathol 216:131–140. doi:10.1002/path

    Article  CAS  PubMed  Google Scholar 

  20. Kantola T, Klintrup K, Väyrynen JP et al (2012) Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 107:1729–1736. doi:10.1038/bjc.2012.456

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Hamilton SR, Bosman FT, Boffetta P et al (2010) Carcinoma of the colon and rectum. In: Bosman F, Carneiro F, Hruban R, Theise N (eds) WHO Classif. tumours Dig. Syst. IARC Press, Lyon, pp 134–146

    Google Scholar 

  22. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours. Wiley-Liss, New York

    Google Scholar 

  23. Väyrynen JP, Vornanen J, Tervahartiala T et al (2012) Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. Int J Cancer 131:E463–E474. doi:10.1002/ijc.26435

    Article  PubMed  Google Scholar 

  24. Väyrynen JP, Sajanti SA, Klintrup K et al (2014) Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer 134:2126–2135. doi:10.1002/ijc.28533

    Article  PubMed  Google Scholar 

  25. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331–371. doi:10.1152/physrev.00030.2001

    CAS  PubMed  Google Scholar 

  26. Duncan R, Carpenter B, Main LC et al (2008) Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98:426–433. doi:10.1038/sj.bjc.6604128

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Quiskamp N, Poeter M, Raabe CA et al (2014) The tumor suppressor annexin A10 is a novel component of nuclear paraspeckles. Cell Mol Life Sci 71:311–329. doi:10.1007/s00018-013-1375-4

    Article  CAS  PubMed  Google Scholar 

  28. Lu S-H, Yuan R-H, Chen Y-L et al (2013) Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system. Histopathology 63:640–648. doi:10.1111/his.12229

    PubMed  Google Scholar 

  29. Kim J, Kim MA, Jee CD et al (2009) Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int J Cancer 125:1842–1850. doi:10.1002/ijc.24541

    Article  CAS  PubMed  Google Scholar 

  30. Kim JKYU, Kim PUMJ, Jung KHWA et al (2010) Decreased expression of Annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression. Oncol Rep 24:607–612. doi:10.3892/or

    CAS  PubMed  Google Scholar 

  31. Munksgaard PP, Mansilla F, Brems Eskildsen A-S et al (2011) Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer 105:1379–1387. doi:10.1038/bjc.2011.404

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Liu S-H, Lin C-Y, Peng S-Y et al (2002) Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 160:1831–1837. doi:10.1016/S0002-9440(10)61129-7

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Patsos G, Germann A, Gebert J, Dihlmann S (2010) Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 126:1838–1849. doi:10.1002/ijc.24905

    CAS  PubMed  Google Scholar 

  34. Gonzalo DH, Lai KK, Shadrach B et al (2013) Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol 230:420–429. doi:10.1002/path.4200

    Article  CAS  PubMed  Google Scholar 

  35. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290. doi:10.1038/sj.onc.1210421

    Article  CAS  PubMed  Google Scholar 

  36. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6:479–507. doi:10.1146/annurev-pathol-011110-130235

    Article  CAS  PubMed  Google Scholar 

  37. Shimizu T, Kasamatsu A, Yamamoto A et al (2012) Annexin A10 in human oral cancer: Biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PLoS One 7:e45510. doi:10.1371/journal.pone.0045510

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Haigis KM, Kendall KR, Wang Y et al (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600–608. doi:10.1038/ng.115

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Rad R, Cadiñanos J, Rad L et al (2013) A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24:15–29. doi:10.1016/j.ccr.2013.05.014

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Yeh JJ, Routh ED, Rubinas T et al (2009) KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8:834–843. doi:10.1158/1535-7163.MCT-08-0972

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to express their gratitude to Ms Riitta Vuento for her excellent assistance in the preparation of study material. This study was supported by grants from the Academy of Finland, Emil Aaltonen Foundation, Finnish Cancer Society, Finnish Foundation for Gastroenterological Research, Finnish Medical Foundation, Northern Finland Cancer Foundation, and Orion-Farmos Research Foundation, Oulu University Scholarship Foundation.

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Oulu, POB 5000, 90014, Oulu, Finland

    Sara A. Sajanti, Juha P. Väyrynen, Päivi Sirniö, Anne Tuomisto & Markus J. Mäkinen

  2. Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu, Finland

    Sara A. Sajanti, Juha P. Väyrynen, Päivi Sirniö, Kai Klintrup, Jyrki Mäkelä, Anne Tuomisto & Markus J. Mäkinen

  3. Department of Surgery, University of Oulu, POB 5000, 90014, Oulu, Finland

    Kai Klintrup & Jyrki Mäkelä

Authors
  1. Sara A. Sajanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juha P. Väyrynen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Päivi Sirniö
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kai Klintrup
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jyrki Mäkelä
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anne Tuomisto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Markus J. Mäkinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus J. Mäkinen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sajanti, S.A., Väyrynen, J.P., Sirniö, P. et al. Annexin A10 is a marker for the serrated pathway of colorectal carcinoma. Virchows Arch 466, 5–12 (2015). https://doi.org/10.1007/s00428-014-1683-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-014-1683-6

Keywords

Search

Navigation